High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. 1995

A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
Department of Medicine B. Radiotherapy, Institut Gustave Roussy, Villejuif, France.

OBJECTIVE The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen. METHODS Between January 1991 and November 1993, 40 patients with progressive ASTS were entered onto the study. Twenty-eight patients had been pretreated with a multidrug regimen that contained SDI and were classified as follows: SDI-refractory (n = 21), SDI-resistant (n = 2), and indeterminate SDI-sensitive (n = 5). Patients were treated until progression or major toxicity. RESULTS One hundred forty-seven cycles of HDI were administered. Neutropenia was dose-limiting, with 100% of patients experiencing grade 3 to 4 toxicity and 12 admissions for febrile neutropenia (30% of patients). Neurotoxicity (17% of patients) was significantly associated with acute renal failure (n = 4) (P < .001), grade 4 thrombocytopenia (P < .01) and febrile neutropenia (P = .048). Chronic renal toxicity (n = 4) was significantly associated with retroperitoneal masses and/or prior nephrectomy (P = .008). Partial responses (PRs) were observed in 12 of 36 assessable patients (33%) and eight patients (22%) experienced disease stabilization. All but one response occurred in patients pretreated with SDI, with five PRs among SDI-refractory patients. Leiomyosarcomas appear resistant to HDI. The median response duration was 8 months (range, 6 to 13+) and the median overall survival time was 12 months. CONCLUSIONS The activity of HDI in these pretreated ASTS patients and the apparent circumvention of SDI resistance suggest a real dose-response relationship for ifosfamide and deserve further evaluation. Although toxic, this treatment appears feasible and manageable using routine clinical support. Since prophylaxis of ifosfamide-induced renal damage remains unknown, frequent monitoring of renal and tubular functions during therapy is highly recommended.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
June 1996, Seminars in oncology,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
April 1992, Annals of oncology : official journal of the European Society for Medical Oncology,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
December 2004, Experimental oncology,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
September 1993, Annals of oncology : official journal of the European Society for Medical Oncology,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
January 1999, Annals of oncology : official journal of the European Society for Medical Oncology,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
August 1998, Annals of oncology : official journal of the European Society for Medical Oncology,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
November 2006, British journal of cancer,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
January 2000, Anticancer research,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
August 1998, Annals of oncology : official journal of the European Society for Medical Oncology,
A Le Cesne, and E Antoine, and M Spielmann, and T Le Chevalier, and E Brain, and C Toussaint, and N Janin, and L Kayitalire, and F Fontaine, and J Genin
November 1997, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!